Draupnir Bio

Executive Summary

Draupnir Bio is a Danish biotechnology company pioneering a novel approach to targeted protein degradation (TPD) by leveraging the lysosomal pathway to eliminate extracellular and membrane-bound pathogenic proteins. Founded in 2021 as a spin-out from Aarhus University and the Max-Planck Society, the company develops oral, small molecule degraders that harness the cell's natural lysosomal machinery, offering a therapeutic strategy distinct from ubiquitin-proteasome-based TPD. Backed by a syndicate of leading European life science investors, Draupnir addresses a significant unmet need in diseases driven by extracellular or membrane proteins that are difficult to target with conventional modalities. While still in early preclinical stages, the company's unique technology platform has the potential to expand the druggable proteome and create new treatment paradigms for oncology, immunology, and rare diseases.

Upcoming Catalysts (preview)

• 2026Series A or B Financing70% success
• 2027Lead Program Nomination and IND-Enabling Studies Initiation60% success
• 2026Presentation of Preclinical Proof-of-Concept Data at a Major Conference80% success